Skip to main content
. 2017 Oct 10;12(10):e0185198. doi: 10.1371/journal.pone.0185198

Fig 3.

Fig 3

A and B. Cost-effectiveness acceptability curves showing the probability that each non-curative palliative treatment strategy: i) TACE alone or TACE+sorafenib; ii) non-sorafenib chemotherapy alone; or iii) sorafenib alone is cost-effective compared with no treatment or BSC for a given willingness-to-pay threshold for an additional (A) life year (LY); and (B) quality adjusted life year (QALY).